Case seriesResults of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Under a Creative Commons license
open access
Keywords
MK-2206
AKT inhibitor
PI3K/AKT pathway
PTEN
Platinum resistant ovarian cancer
Serous ovarian carcinoma
Cited by (0)
- 1
Present address: Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR.
© 2020 The Authors. Published by Elsevier Inc.